Antony Odell, chief executive at (), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue.
The group, which already has experience of commercialising products in the US, is planning a commercial launch in the second half of 2016.
SurgiPure XD will treat the most complex types of hernias, a market worth in itself US$300 mln.
He says is "a busy little company" that is "advancing on many fronts."
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE